NetScientific: refinanced and focused on enhancing value

0
15
  • NetScientific unit ProAxis secures US patent for bone disease screening technology
NetScientific PLC -

Quick facts: NetScientific PLC

Follow

View company profile

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

22 Oct 2021

NetScientic PLC said its subsidiary ProAxis Ltd has won approval for a key US patent for technology that can be used to screen, identify and monitor people at risk of bone disease.

The company said the patent for its K-POSTN Assay, which it intends to launch shortly, is a significant step towards measuring bone health for patients at high risk of osteoporotic fractures.

ProAxsis is working with the expert Bone Health team led by Professor Serge () at the University of Geneva to create a novel and patented bone-specific enzyme-linked immunoassay (ELISA) for the detection of serum K-POSTN, which can be used to predict fractures in post-menopausal women.

Dr David Ribeiro, CEO of ProAxsis, commented: “The K-POSTN assay has the potential to help healthcare professionals screen, identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases, thus enabling early therapeutic intervention which will decrease the burden on the health service and increase quality of life for the patient.

Read more

21 Oct 2021

() noted that the temporary suspension by portfolio company () of patient recruitment for one of their clinical studies is not expected to affect the overall timing of clinical data.

PDS issued a statement announcing that the Phase 2 clinical trial led by the National Cancer Institute (NCI), evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers, had paused recruitment due to an issue that is not specific to the trial itself.

Read more

05 Oct 2021

NetScientific PLC (AIM:NSCI, FRA:NTK1) said investee company PDS Biotechnology Corporation (NASDAQ:PDSB) has completed enrolment of the first stage of its phase II head and neck cancer clinical trial.

The checkpoint inhibitor naive arm of its VERSATILE-002 study will treat people with recurrent and/or metastatic human papillomavirus (HPV16) form of the disease.

Read more

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

NetScientific says results mark ‘end of turnaround period, which has been…

NetScientific PLC (AIM:NSCI, FRA:NTK1) (AIM:NSCI, FRA:NTK1) chief executive, Dr Ilian Iliev joins Proactive to discuss their interim results results and statement.

The results for the six months ended June 30 showed the loss for the period was almost GBP1.5mln, reflecting the investments in…

3 weeks, 2 days ago

5 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here